$9.05
4.75% day before yesterday
Nasdaq, Sep 06, 10:00 pm CET
ISIN
US56600D1072
Symbol
MRVI

Maravai LifeSciences Stock price

$9.05
-0.04 0.44% 1M
+1.77 24.31% 6M
+2.50 38.17% YTD
-1.80 16.59% 1Y
-49.56 84.56% 3Y
-20.80 69.68% 5Y
-20.80 69.68% 10Y
Nasdaq, Closing price Fri, Sep 06 2024
+0.41 4.75%
ISIN
US56600D1072
Symbol
MRVI
Sector
Industry

Key metrics

Market capitalization $1.28b
Enterprise Value $1.61b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.78
P/S ratio (TTM) P/S ratio 4.60
P/B ratio (TTM) P/B ratio 2.93
Revenue growth (TTM) Revenue growth -48.78%
Revenue (TTM) Revenue $278.59m
EBIT (operating result TTM) EBIT $-38.57m
Free Cash Flow (TTM) Free Cash Flow $-16.92m
Cash position $573.17m
EPS (TTM) EPS $-1.00
P/E forward negative
P/S forward 4.65
EV/Sales forward 5.84
Short interest 7.12%
Show more

Is Maravai LifeSciences a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.

Maravai LifeSciences Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Maravai LifeSciences forecast:

11x Buy
73%
4x Hold
27%

Analyst Opinions

15 Analysts have issued a Maravai LifeSciences forecast:

Buy
73%
Hold
27%

Financial data from Maravai LifeSciences

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '24
+/-
%
279 279
49% 49%
100%
- Direct Costs 163 163
4% 4%
59%
115 115
69% 69%
41%
- Selling and Administrative Expenses 80 80
2% 2%
29%
- Research and Development Expense 19 19
3% 3%
7%
16 16
94% 94%
6%
- Depreciation and Amortization 54 54
33% 33%
20%
EBIT (Operating Income) EBIT -39 -39
116% 116%
-14%
Net Profit -132 -132
275% 275%
-47%

In millions USD.

Don't miss a Thing! We will send you all news about Maravai LifeSciences directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Maravai LifeSciences Stock News

Positive
Reuters
22 days ago
Repligen , a provider of drug manufacturing equipment, has approached Maravai LifeSciences Holdings , a vaccine capping reagent vendor that has a market value of $2.2 billion, with an acquisition offer, people familiar with the matter said on Friday.
Neutral
GlobeNewsWire
26 days ago
SAN DIEGO, Aug. 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences in August and September.
Neutral
Seeking Alpha
about one month ago
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI ) Q2 2024 Results Conference Call August 7, 2024 5:00 PM ET Company Participants Deborah Hart - Head, Investor Relations Trey Martin - Chief Executive Officer Kevin Herde - Chief Financial Officer Drew Burch - President, Nucleic Acid Production Becky Buzzeo - Chief Commercial Officer Conference Call Participants Catherine Schulte - Baird Tejas Sa...
More Maravai LifeSciences News

Company Profile

Maravai Lifesciences Holdings, Inc. operates as an investment holding company. It develops biopharmaceuticals. The company is headquartered in San Diego, CA.

Head office United States
CEO William Martin
Employees 650
Founded 2014
Website www.maravai.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today